NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

INBX

Inhibrx Biosciences Inc

Jul 03 • 01:30PM ET

16.33

Dollar change +0.59
Percentage change 3.75	%

Healthcare • Biotechnology • USA • NASD

Peers: BPMC ARVN ONC PTCT EXEL PBYI ADAP KPTI IGMS

| Held by: VTI IWM VXF IWN IBB VTWO FESM EES IWC PRFZ

Scroll to Statements

Index	RUT	P/E	0.14	EPS (ttm)	119.22	Insider Own	31.84%	Shs Outstand	14.48M	Perf Week	10.41%
Market Cap	236.39M	Forward P/E	-	EPS next Y	-9.24	Insider Trans	0.00%	Shs Float	9.87M	Perf Month	20.69%
Enterprise Value	126.40M	PEG	-	EPS next Q	-2.76	Inst Own	62.57%	Short Float	7.93%	Perf Quarter	15.82%
Income	1.72B	P/S	1181.95	EPS this Y	-109.95%	Inst Trans	-4.24%	Short Ratio	7.50	Perf Half Y	7.86%
Sales	0.20M	P/B	2.50	EPS next Y	17.54%	ROA	648.69%	Short Interest	0.78M	Perf YTD	6.04%
Book/sh	6.52	P/C	1.09	EPS next 5Y	-	ROE	3250.55%	52W High	17.79 -8.21%	Perf Year	18.85%
Cash/sh	14.96	P/FCF	-	EPS past 3/5Y	- -	ROIC	865.81%	52W Low	10.80 51.20%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-69.79% -	Gross Margin	-1199.50%	Volatility	5.54% 5.85%	Perf 5Y	-
Dividend TTM	-	EV/Sales	632.00	EPS Y/Y TTM	-	Oper. Margin	-150262.00%	ATR (14)	0.84	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.12	Sales Y/Y TTM	-	Profit Margin	861485.50%	RSI (14)	68.23	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.12	EPS Q/Q	48.50%	SMA20	11.10%	Beta	-0.14	Target Price	12.00
Payout	0.00%	Debt/Eq	1.13	Sales Q/Q	-	SMA50	22.86%	Rel Volume	0.51	Prev Close	15.74
Employees	161	LT Debt/Eq	1.11	Earnings	May 14 AMC	SMA200	15.97%	Avg Volume	104.30K	Price	16.33
IPO	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.23% -	Trades		Volume	53,380	Change	3.75%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	JMP Securities	Mkt Perform

May-14-25 04:05PM	Inhibrx Reports First Quarter 2025 Financial Results (PR Newswire) +10.89%
Apr-01-25 04:05PM	Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President (PR Newswire)
Mar-17-25 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
Jan-21-25 05:01PM	Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer (PR Newswire) +5.19%
Jan-13-25 04:15PM	Inhibrx Biosciences Announces Loan Agreement with Oxford Finance (PR Newswire) -6.60%
04:24PM	Loading…
Nov-14-24 04:24PM	Inhibrx Biosciences Reports Third Quarter 2024 Financial Results (PR Newswire) -7.25%
Nov-04-24 04:00PM	Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation (PR Newswire)
Sep-13-24 01:55AM	Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) (GuruFocus.com) +8.82%
Aug-13-24 06:54PM	Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (PR Newswire)
May-24-24 04:00PM	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi (PR Newswire)
May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kayyem Jon Faiz	Director	Nov 19 '24	Buy	14.23	69,686	991,416	51,093	Nov 22 04:03 PM
Kayyem Jon Faiz	Director	Nov 20 '24	Buy	14.19	37,500	532,204	69,843	Nov 22 04:03 PM
Lappe Mark	Chief Executive Officer	Sep 12 '24	Buy	15.05	26,963	405,793	692,511	Sep 16 05:12 PM
Lappe Mark	Chief Executive Officer	Sep 16 '24	Buy	17.13	13,037	223,324	705,548	Sep 16 05:12 PM
Vuori Kristiina MD	Director	Sep 11 '24	Buy	15.07	6,457	97,307	13,776	Sep 12 05:14 PM
Vuori Kristiina MD	Director	Sep 10 '24	Buy	15.00	179	2,685	7,319	Sep 12 05:14 PM
Lappe Mark	Chief Executive Officer	Sep 06 '24	Buy	15.29	26,000	397,540	647,548	Sep 10 05:00 PM
Lappe Mark	Chief Executive Officer	Sep 09 '24	Buy	15.21	9,500	144,495	657,048	Sep 10 05:00 PM
Lappe Mark	Chief Executive Officer	Sep 10 '24	Buy	15.19	8,500	129,115	665,548	Sep 10 05:00 PM
Lappe Mark	Chief Executive Officer	Sep 03 '24	Buy	15.81	20,000	316,263	165,000	Sep 03 05:31 PM
Lappe Mark	Chief Executive Officer	Aug 29 '24	Buy	14.03	10,000	140,300	135,000	Sep 03 05:31 PM
Lappe Mark	Chief Executive Officer	Aug 30 '24	Buy	14.02	10,000	140,200	145,000	Sep 03 05:31 PM
Vuori Kristiina MD	Director	Aug 29 '24	Buy	14.00	7,140	99,960	7,140	Sep 03 04:27 PM
MANHARD KIMBERLY	Director	Aug 28 '24	Buy	13.98	10,000	139,800	10,000	Aug 30 04:16 PM
FORSYTH DOUGLAS	Director	Aug 23 '24	Buy	14.07	59,812	841,555	224,564	Aug 26 04:26 PM
FORSYTH DOUGLAS	Director	Aug 22 '24	Buy	12.89	15,188	195,773	164,752	Aug 26 04:26 PM
Lappe Mark	Chief Executive Officer	Aug 20 '24	Buy	12.97	27,055	350,903	41,920	Aug 22 04:29 PM
Lappe Mark	Chief Executive Officer	Aug 21 '24	Buy	12.93	12,945	167,379	54,865	Aug 22 04:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INBX

Inhibrx Biosciences Inc

Upgrade your FINVIZ experience